Cerebral air embolism: neurologic manifestations, prognosis, and outcome

Front Neurol. 2024 Jun 19:15:1417006. doi: 10.3389/fneur.2024.1417006. eCollection 2024.

Abstract

Background: Cerebral air embolism (CAE) is an uncommon medical emergency with a potentially fatal course. We have retrospectively analyzed a set of patients treated with CAE at our comprehensive stroke center and a hyperbaric medicine center. An overview of the pathophysiology, causes, diagnosis, and treatment of CAE is provided.

Results: We retrospectively identified 11 patients with cerebral venous and arterial air emboli that highlight the diversity in etiologies, manifestations, and disease courses encountered clinically. Acute-onset stroke syndrome and a progressive impairment of consciousness were the two most common presentations in four patients each (36%). Two patients (18%) suffered from an acute-onset coma, and one (9%) was asymptomatic. Four patients (36%) were treated with hyperbaric oxygen therapy (HBTO), high-flow oxygen therapy without HBOT was started in two patients (18%), two patients (18%) were in critical care at the time of diagnosis and three (27%) received no additional treatment. CAE was fatal in five cases (46%), caused severe disability in two (18%), mild disability in three (27%), and a single patient had no lasting deficit (9%).

Conclusion: Cerebral air embolism is a dangerous condition that necessitates high clinical vigilance. Due to its diverse presentation, the diagnosis can be missed or delayed in critically ill patients and result in long-lasting or fatal neurological complications. Preventative measures and a proper diagnostic and treatment approach reduce CAE's incidence and impact.

Keywords: air embolism; cerebral embolism; cerebral stroke; hyperbaric oxygen therapy; neurological emergency.

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. RH and VW were supported by Charles University, Czech Republic (Cooperatio Program, research area NEUR). RH was supported by the Ministry of Health of the Czech Republic (grant No. DRO–UHHK 00179906).